BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 2260040)

  • 1. [When can the cases of toxic or adverse effects of drugs be rejected? 80 cases].
    Lagier G; Castot A; Sabouraud S; de Cremoux P; Efthymiou ML
    Therapie; 1990; 45(5):435-6. PubMed ID: 2260040
    [No Abstract]   [Full Text] [Related]  

  • 2. [Postmarketing surveillance of adverse reactions of drugs].
    Polli EE; Cortellaro M
    Ann Ital Med Int; 1989; 4(1):1-9. PubMed ID: 2702012
    [No Abstract]   [Full Text] [Related]  

  • 3. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France].
    Bégaud B; Evreux JC; Jouglard J; Lagier G
    Therapie; 1985; 40(2):111-8. PubMed ID: 4002188
    [No Abstract]   [Full Text] [Related]  

  • 4. [Mandatory report of adverse effects of drugs: has the order modified the spontaneous notification?].
    Haramburu F; Pere JC; Begaud B; Albin H
    Therapie; 1988; 43(6):493-6. PubMed ID: 3227516
    [No Abstract]   [Full Text] [Related]  

  • 5. [Methods for studying the adverse effects of drugs. I. Comparison of imputability methods: modelling and methodology].
    Péré JC; Begaud B; Haramburu F; Albin H
    Therapie; 1984; 39(3):279-89. PubMed ID: 6463953
    [No Abstract]   [Full Text] [Related]  

  • 6. Measuring adverse drug reactions in a postmarketing surveillance system.
    Fisher S; Bryant SG; Kluge RM
    Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 8. [Minimal information that should be found in reports about suspected adverse reactions of drugs].
    Laporte JR; Lience E
    Med Clin (Barc); 1991 Jun; 97(2):56-7. PubMed ID: 1895784
    [No Abstract]   [Full Text] [Related]  

  • 9. [Computerized detection of new adverse effects in drug surveillance. A proposal for the periodic use of the French data bank].
    Pham E; Ventre JJ; Saddier P; Descotes J; Evreux JC
    Therapie; 1988 May; 43(3):235-7. PubMed ID: 3420571
    [No Abstract]   [Full Text] [Related]  

  • 10. Epidemiologic assessment of adverse drug effects.
    Stern RS
    Semin Dermatol; 1989 Sep; 8(3):136-40. PubMed ID: 2701270
    [No Abstract]   [Full Text] [Related]  

  • 11. Monitoring adverse drug reactions in the postmarketing phase.
    Hoigné R; Hottinger S
    Pharm Acta Helv; 1988; 63(1):2-12. PubMed ID: 3283774
    [No Abstract]   [Full Text] [Related]  

  • 12. Scientific challenges in postmarketing surveillance of ocular adverse drug reactions.
    Fraunfelder FW; Fraunfelder FT
    Am J Ophthalmol; 2007 Jan; 143(1):145-149. PubMed ID: 17188050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Information centers on undesirable effects of drugs: also on alerting function].
    Bégaud B; Péré JC; Tubert P; Barat C; Haramburu F; Albin H
    Therapie; 1987; 42(2):231-7. PubMed ID: 3617000
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods].
    Lagier G; Vincens M; Lefebure B; Frelon JH
    Therapie; 1983; 38(3):295-302. PubMed ID: 6612666
    [No Abstract]   [Full Text] [Related]  

  • 16. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 17. Adverse drug reactions.
    Turner P
    Hum Toxicol; 1986 May; 5(3):161-2. PubMed ID: 3710492
    [No Abstract]   [Full Text] [Related]  

  • 18. Nonlinear neural mapping analysis of the adverse effects of drugs.
    Domine D; Guillon C; Devillers J; Lacroix R; Lacroix J; Doré JC
    SAR QSAR Environ Res; 1998; 8(1-2):109-20. PubMed ID: 9517012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies in adverse drug reaction reporting.
    Juergens JP
    Am J Hosp Pharm; 1990 Jan; 47(1):76-7. PubMed ID: 2301428
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of backgrounds in safety analysis: the impact of comparison cases on what you see.
    Gogolak VV
    Pharmacoepidemiol Drug Saf; 2003; 12(3):249-52. PubMed ID: 12733479
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.